Bigner spent years trying to make monoclonal antibodies against the mutant protein.

FORBES: Magazine Article

This was controversial at first, but Slamon persuaded Genentech to test a monoclonal antibody that would block this protein.

FORBES: Targeting Tumors

Both drugs are monoclonal antibodies that are supposed to attach to the amyloid protein and clear it from the brain.

WSJ: For Alzheimer's, a Fork in the Road